Gwen Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Ms. Melincoff is currently Managing Director at Gemini Advisors LLC and an advisor to Phase 1 Ventures and Verge Genomics. Previously, she served as Vice President of Business Development at BTG International Inc., a UK-specialist healthcare company.
Prior to BTG, Ms. Melincoff was Senior Vice President of Business Development at Shire Plc. Additionally, she led the Shire Strategic Investment Group, the venture capital arm of Shire Plc. Prior to joining Shire Plc, Ms. Melincoff held managerial and business development positions at various pharmaceutical companies, such as Adolor Corporation. Ms. Melincoff currently serves on the Boards of Directors of Gain Therapeutics, Protalix BioTherapeutics, Inc. (PLX) and Soleno Therapeutics (SLNO). Previously, she served as a board member or observer on the boards of Photocure ASA, Tobira Therapeutics (acquired by Allergan), DBV Technologies, AM Pharma, ArmaGen Technologies, Promethera Biosciences, Naurex Inc. (acquired by Allergan), Kamada Ltd. (KMDA), and Enterome. Ms. Melincoff holds a B.S. in Biology from The George Washington University and an M.S. in Management and Health Care Administration from Pennsylvania State University. Ms. Melincoff has also attained the designation of Certified Licensing Professional (CLP™). Ms. Melincoff was named one of the “Top Women in Biotech 2013” by Fierce Biotech as well as being named to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013.